Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


19.02.2018

4 BJU Int
1 BMC Cancer
2 Br J Cancer
1 Br J Radiol
1 Cancer Lett
4 Cancer Res
1 Curr Treat Options Oncol
1 Endocrinology
1 Eur J Radiol
2 Eur Radiol
18 Eur Urol
1 Hum Pathol
3 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
3 J Magn Reson Imaging
3 J Urol
1 N Engl J Med
3 Nat Rev Urol
1 Oncogene
2 PLoS One
2 Prostate
2 Ther Adv Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. THURTLE D, Barrett T, Thankappan-Nair V, Koo B, et al
    Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14166.
    PubMed     Text format     Abstract available

  2. SOORIAKUMARAN P
    Surgery for oligometastatic prostate cancer: ready for prime time?
    BJU Int. 2018 Feb 12. doi: 10.1111/bju.14038.
    PubMed     Text format    

  3. BOLTON EM, Lynch TH
    Are all gonadotropin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14168.
    PubMed     Text format     Abstract available

  4. ALTOK M, Babaian K, Achim MF, Achim GC, et al
    Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection.
    BJU Int. 2018 Feb 15. doi: 10.1111/bju.14164.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2018 Feb 13. pii: bjc20186. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available

  7. SAUNDERS EJ, Dadaev T, Leongamornlert DA, Al Olama AA, et al
    Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Br J Cancer. 2018 Feb 13. pii: bjc2017468. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Br J Radiol

  8. GODDARD L, Brodin NP, Bodner WR, Garg M, et al
    Comparing photon and proton based hypofractioned sbrt for prostate cancer accounting for robustness and realistic treatment deliverability.
    Br J Radiol. 2018 Feb 13:20180010. doi: 10.1259/bjr.20180010.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. LIN W, Luo J, Sun Y, Lin C, et al
    ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30132.
    PubMed     Text format     Abstract available


    Cancer Res

  10. JUNG Y, Cackowski FC, Yumoto K, Decker A, et al
    CXCL12gamma Promotes Development of Metastatic Castration Resistant Prostate Cancer by Induction of Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2018 Feb 5. pii: 0008-5472.CAN-17-2332.
    PubMed     Text format     Abstract available

  11. BHAGIRATH D, Yang TL, Bucay N, Sekhon K, et al
    MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer.
    Cancer Res. 2018 Feb 1. pii: 0008-5472.CAN-17-2069.
    PubMed     Text format     Abstract available

  12. XIAO L, Wang Y, Xu K, Hu H, et al
    Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-2341.
    PubMed     Text format     Abstract available

  13. LACHANCE J, Berens AJ, Hansen MEB, Teng AK, et al
    Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-1550.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  14. SANHUEZA C, Kohli M
    Clinical and Novel Biomarkers in the Management of Prostate Cancer.
    Curr Treat Options Oncol. 2018;19:8.
    PubMed     Text format     Abstract available


    Endocrinology

  15. KAWANAMI T, Tanaka T, Hamaguchi Y, Nomiyama T, et al
    Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation.
    Endocrinology. 2018 Feb 12. pii: 4850601. doi: 10.1210/en.2018-00099.
    PubMed     Text format     Abstract available


    Eur J Radiol

  16. ULLRICH T, Quentin M, Oelers C, Dietzel F, et al
    Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality.
    Eur J Radiol. 2017;90:192-197.
    PubMed     Text format     Abstract available


    Eur Radiol

  17. OLSON MC, Atwell TD, Mynderse LA, King BF, et al
    CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13-year single-center experience.
    Eur Radiol. 2017;27:3326-3332.
    PubMed     Text format     Abstract available

  18. MUELLER-LISSE UG, Murer S, Mueller-Lisse UL, Kuhn M, et al
    Everyman's prostate phantom: kiwi-fruit substitute for human prostates at magnetic resonance imaging, diffusion-weighted imaging and magnetic resonance spectroscopy.
    Eur Radiol. 2017;27:3362-3371.
    PubMed     Text format     Abstract available


    Eur Urol

  19. BRAJTBORD JS, Leapman MS, Cooperberg MR
    The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Eur Urol. 2017;71:705-709.
    PubMed     Text format     Abstract available

  20. WEGELIN O, van Melick HHE, Hooft L, Bosch JLHR, et al
    Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Techniqu
    Eur Urol. 2017;71:517-531.
    PubMed     Text format     Abstract available

  21. DASKIVICH TJ, Spiegel B, Kim HL
    Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the Art.
    Eur Urol. 2017;71:311-312.
    PubMed     Text format     Abstract available

  22. BORGHESI M, Ahmed H, Nam R, Schaeffer E, et al
    Complications After Systematic, Random, and Image-guided Prostate Biopsy.
    Eur Urol. 2017;71:353-365.
    PubMed     Text format     Abstract available

  23. TOSOIAN JJ, Almutairi F, Morais CL, Glavaris S, et al
    Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Eur Urol. 2017;71:697-700.
    PubMed     Text format     Abstract available

  24. KISHAN AU, Shaikh T, Wang PC, Reiter RE, et al
    Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Eur Urol. 2017;71:766-773.
    PubMed     Text format     Abstract available

  25. FOSSATI N, Wiklund P, Rochat CH, Montorsi F, et al
    Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.
    Eur Urol. 2017;71:307-308.
    PubMed     Text format     Abstract available

  26. FROEHNER M, Koch R, Hubler M, Zastrow S, et al
    Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older.
    Eur Urol. 2017;71:710-713.
    PubMed     Text format     Abstract available

  27. COOPERBERG MR, Brooks JD, Faino AV, Newcomb LF, et al
    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30067.
    PubMed     Text format     Abstract available

  28. ANTONARAKIS ES, Lu C, Luber B, Liang C, et al
    Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30089.
    PubMed     Text format     Abstract available

  29. HAESE A
    Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30086.
    PubMed     Text format    

  30. FAIENA I, Salmasi A, Pantuck AJ, Drakaki A, et al
    Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30077.
    PubMed     Text format    

  31. MATEO J, Cheng HH, Beltran H, Dolling D, et al
    Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    Eur Urol. 2018 Jan 29. pii: S0302-2838(18)30019.
    PubMed     Text format     Abstract available

  32. AMINSHARIFI A, Polascik TJ
    Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
    Eur Urol. 2018 Feb 7. pii: S0302-2838(18)30076.
    PubMed     Text format    

  33. ADAM M, Tennstedt P, Lanwehr D, Tilki D, et al
    Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Eur Urol. 2017;71:330-336.
    PubMed     Text format     Abstract available

  34. HE J, Albertsen PC, Moore D, Rotter D, et al
    Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    Eur Urol. 2017;71:760-763.
    PubMed     Text format     Abstract available

  35. LEAPMAN MS, Cowan JE, Simko J, Roberge G, et al
    Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Eur Urol. 2017;71:750-759.
    PubMed     Text format     Abstract available

  36. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


    Hum Pathol

  37. ERICKSON A, Sandeman K, Lahdensuo K, Nordling S, et al
    New prostate cancer grade grouping system predicts survival after radical prostatectomy.
    Hum Pathol. 2018 Feb 12. pii: S0046-8177(18)30048.
    PubMed     Text format    


    Int J Cancer

  38. SHAO Y, Ye G, Ren S, Piao HL, et al
    Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31313.
    PubMed     Text format     Abstract available

  39. QU S, Xue H, Dong X, Lin D, et al
    Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31310.
    PubMed     Text format     Abstract available

  40. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Post-diagnosis alcohol intake and prostate cancer survival: A population-based cohort study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31307.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  41. VIGNEAULT E, Martell K, Taussky D, Husain S, et al
    Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
    Int J Radiat Oncol Biol Phys. 2017 Dec 28. pii: S0360-3016(17)34499.
    PubMed     Text format     Abstract available


    J Clin Oncol

  42. TSAO CK, Oh WK
    First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
    J Clin Oncol. 2018 Feb 12:JCO2017774315. doi: 10.1200/JCO.2017.77.4315.
    PubMed     Text format    


    J Magn Reson Imaging

  43. WANG J, Wu CJ, Bao ML, Zhang J, et al
    Using support vector machine analysis to assess PartinMR: A new prediction model for organ-confined prostate cancer.
    J Magn Reson Imaging. 2018 Feb 13. doi: 10.1002/jmri.25961.
    PubMed     Text format     Abstract available

  44. STRAUB S, Laun FB, Emmerich J, Jobke B, et al
    Potential of quantitative susceptibility mapping for detection of prostatic calcifications.
    J Magn Reson Imaging. 2017;45:889-898.
    PubMed     Text format     Abstract available

  45. BRUNSING RL, Schenker-Ahmed NM, White NS, Parsons JK, et al
    Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.
    J Magn Reson Imaging. 2016 Aug 16. doi: 10.1002/jmri.25419.
    PubMed     Text format     Abstract available


    J Urol

  46. NABHANI JA, Kuang R, Liu H, Kwan L, et al
    Health Changes in Low-income Men Transitioning from a State-funded Prostate Cancer Program to Comprehensive Insurance.
    J Urol. 2018 Feb 6. pii: S0022-5347(18)30183-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  47. OZGUR BC
    Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
    J Urol. 2018 Feb 8. pii: S0022-5347(17)78117-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  48. BAPAT B
    Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Lobl
    J Urol. 2018 Feb 8. pii: S0022-5347(18)30001-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    N Engl J Med

  49. CHEN D, Ayala GE
    Innervating Prostate Cancer.
    N Engl J Med. 2018;378:675-677.
    PubMed     Text format    


    Nat Rev Urol

  50. LEE P, Gujar S
    Potentiating prostate cancer immunotherapy with oncolytic viruses.
    Nat Rev Urol. 2018 Feb 13. pii: nrurol.2018.10. doi: 10.1038/nrurol.2018.
    PubMed     Text format     Abstract available

  51. KELSEY R
    Prostate cancer: Genomic drivers of resistance to AR therapies.
    Nat Rev Urol. 2018 Feb 13. pii: nrurol.2018.18. doi: 10.1038/nrurol.2018.
    PubMed     Text format    

  52. HAMMARSTEN J, Damber JE, Haghsheno MA, Mellstrom D, et al
    A stage-dependent link between metabolic syndrome components and incident prostate cancer.
    Nat Rev Urol. 2018 Feb 13. pii: nrurol.2018.8. doi: 10.1038/nrurol.2018.
    PubMed     Text format     Abstract available


    Oncogene

  53. LI N, Truong S, Nouri M, Moore J, et al
    Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3.
    Oncogene. 2018 Feb 12. pii: 10.1038/s41388-017-0098.
    PubMed     Text format     Abstract available


    PLoS One

  54. GILLEBERT Q, Huchet V, Rousseau C, Cochet A, et al
    18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
    PLoS One. 2018;13:e0191487.
    PubMed     Text format     Abstract available

  55. KORONOWICZ AA, Drozdowska M, Wielgos B, Piasna-Slupecka E, et al
    The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.
    PLoS One. 2018;13:e0192860.
    PubMed     Text format     Abstract available


    Prostate

  56. SHOU J, Zhang Q, Wang S, Zhang D, et al
    The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
    Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
    PubMed     Text format     Abstract available

  57. DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
    Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
    PubMed     Text format     Abstract available


    Ther Adv Urol

  58. ABDEL-RAHMAN O
    Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy.
    Ther Adv Urol. 2017;10:35-42.
    PubMed     Text format     Abstract available

  59. MEANI D, Solaric M, Visapaa H, Rosen RM, et al
    Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.
    Ther Adv Urol. 2017;10:51-63.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: